一种新的以细胞表面受体为靶向的基因导入系统

鉴于胰岛素样生长因子Ⅰ号及Ⅱ号的受体 (IGFⅠR ,IGFⅡR)在人原发性肝癌中过量表达 ,以及表皮细胞生长因子受体 (EGFR)在多种人恶性肿瘤过量表达 ,设计和合成了针对IGFⅠR及IGFⅡR的 1 4肽E5和针对EGFR的 1 6肽GE7,以及流感病毒血凝素功能域 2 0肽HA2 0作为内吞小体释放寡肽 (Endosomereleasingoligopeptide,EOP) ,将它们分别与多聚阳离子多肽 (Polycationic polypeptide ,PCP)———多聚赖氨酸 (Polylysine ,PL)或鱼精蛋白 (Protamine,PA)共价连接 ,藉静电效应与DNA形成一个复合体 (E5 PCP/DNA/PCP HA2 0 ,GE7 PCP/DNA/PCP HA2 0 ) ,即构建的新的受体介导的靶向性非病毒型基因导入系统 .体内、外实验结果表明它们相对靶向且高效地将外源基因导入人恶性肿瘤细胞并得到预期表达     

A novel receptor-targeted gene delivery system for cancer gene therapy

Some growth factor receptors, such as insulin like growth factor Ⅰ and Ⅱ receptor (IGF Ⅰ R, IGF Ⅱ R) and epidermal growth factor receptor (EGF R), have been proved to be over-expressed in a variety of human cancers derived from different tissue origins. Based on this molecular alteration, a polypeptide conjugate gene delivery system was designed and synthesized. It contains three essential moieties: a ligand oligopeptide (LOP) for receptor recognition, a polycationic polypeptide (PCP) such as protamine (PA) or poly-L-lysine (PL) as a backbone for DNA binding and an endosome-releasing oligopeptide (EROP) such as influenza baenagglutinin oligopeptide (HA20) for endosomolysis. These components are covalently conjugated as LOP-PCP-HA20 or in the form of a mixture of LOP-PCP and HA20-PCP. A 14 amino acid E5 was designed and synthesized as LOP for IGF Ⅰ R and IGF Ⅱ R, and a 16 amino acid GE7 as LOP for EGF R. Both E5 and GE7 systems could form stable complex with the plasmid DNA as E5-PCP/DNA/PCP-HA20 a     

明胶亲和层析纯化人血浆纤维连接蛋白及其糖链结构的初探

应用明胶亲和层析并结合凝胶过滤的方法,纯化人血浆纤维连接蛋白(Fn),此法仅二步层析,步骤简化且操作简便。纯化的Fn经凝胶电泳鉴定为一条蛋白条带,免疫鉴定仍保持原有的抗原性,得率为36％。用ConA亲和层析鉴定纯化的Fn分子中糖链结构为N-连接型复杂型糖链二天线,此均一糖链结果佐证了Fn的纯度。还对凝胶过滤分离得到的具有Fn抗原性的Fn片段进行了讨论。